BriaCell Therapeutics Corp.
BCT.TO
TSX
| Weiss Ratings | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.10 | |||
| Price History | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 12.28% | |||
| 30-Day Total Return | -31.90% | |||
| 60-Day Total Return | -63.44% | |||
| 90-Day Total Return | -68.42% | |||
| Year to Date Total Return | -57.64% | |||
| 1-Year Total Return | -91.42% | |||
| 2-Year Total Return | -96.35% | |||
| 3-Year Total Return | -96.63% | |||
| 5-Year Total Return | -97.38% | |||
| 52-Week High % Change | -91.35% | |||
| 52-Week Low % Change | 22.86% | |||
| Price | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $61.50 | |||
| 52-Week Low Price | $4.33 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 13, 2024 | |||
| Valuation | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 13.67M | |||
| Enterprise Value | 7.76M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -13.41 | |||
| Earnings Per Share Growth | -48.65% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 3.17 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $5.21 | |||
| Enterprise Value/EBITDA (TTM) | -0.26 | |||
| Enterprise Value/EBIT | -0.26 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.78M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604-921-1810 | |||
| Address | Bellevue Centre West Vancouver, BC V7T 2X1 | |||
| Website | briacell.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -129.07% | |||
| Return on Equity | -- | |||
| Income Statement | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -29.87M | |||
| EBIT (TTM) | -29.98M | |||
| Net Income (TTM) | -16.60M | |||
| Net Income Avl. to Common (TTM) | -16.60M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -197.83% | |||
| EPS Diluted (TTM) | -13.41 | |||
| EPS Diluted Growth (Q YOY) | 55.70% | |||
| Balance Sheet | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.79M | |||
| Cash Per Share (Q) | $3.26 | |||
| Total Current Assets (Q) | 8.22M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 3.71M | |||
| Current Ratio (Q) | 1.648 | |||
| Book Value Per Share (Q) | $1.68 | |||
| Total Assets (Q) | 10.41M | |||
| Total Current Liabilities (Q) | 4.99M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 6.70M | |||
| Total Common Equity (Q) | 4.04M | |||
| Cash Flow | BCT.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -756.80K | |||
| Cash from Financing (TTM) | 16.38M | |||
| Net Change in Cash (TTM) | -7.85M | |||
| Levered Free Cash Flow (TTM) | -11.27M | |||
| Cash from Operations (TTM) | -23.48M | |||
